US Stocks
Durect Corp
Durect Corp

Durect Corp (DRRX)


  • $







Key Stats

Today Low/High$0.73 / $0.77
52 Week Low/High$0.72 / $2.95
P/E ratio-6.52
Market Cap$172.18M

Company Details

DURECT is a biopharmaceutical company committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and potentially lifesaving therapies based on its endogenous epigenetic regulator program. DUR-928, the company's lead drug candidate is in clinical development for the potential treatment of alcohol-associated hepatitis (AH) for which FDA has granted a Fast Track Designation, COVID-19 patients with acute liver or kidney injury, and non-alcoholic steatohepatitis (NASH). DURECT's proprietary drug delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs. One late-stage product candidate in this category is POSIMIR® (bupivacaine sustained-release solution), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.
OrganisationDurect Corp
HeadquatersCupertino, California, US
IndustryHealth Technology
CEOJames Brown

Discover more

Frequently Asked Questions

What is Durect Corp (DRRX) share price today?

Can Indians buy Durect Corp (DRRX) shares?

How can I buy Durect Corp (DRRX) shares from India?

Can Fractional shares of Durect Corp (DRRX) be purchased?

What are the documents required to start investing in Durect Corp (DRRX) stocks?